Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 The ETC (Emerging Technology ... innovation centers, announced today that applications for AccelerateBaltimore™ ... 1st. “Do you have a big idea?,” asked ... to know about it. AccelerateBaltimore helps you and ... in just 13 weeks.” Interested game changers ...
(Date:11/26/2014)... CA (PRWEB) November 25, 2014 Silicon ... joins forces with RPM Alliance , provider of ... pharmaceutical companies. With the latest addition to its CRO ... free validated EDC system to India. , “We ... a robust and customizable EDC platform which is both ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le ... au salon Hi Europe 2014 (du 2 au ... Curcumine la plus biodisponible actuellement sur le ... des ingrédients approuvés par les règlements européens. ... dans la racine de curcuma ( Curcuma longa ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... in U.S. dollars, QUEBEC CITY, May 7 /PRNewswire-FirstCall/ ... a global biopharmaceutical company focused on,endocrinology and oncology, today ... March 31, 2008., First Quarter 2008 Highlights, ... trial of the Phase 3 program ...
... 1Q08 -- -- 1Q08 Net ... $0.12 versus 1Q07 Diluted EPS $.10 on 11.6 Million ... Additional Shares --, NEW ... company dedicated to,improving health through the development, manufacture and commercialization,of a broad range ...
... potential as a super material is blighted by the ... form of an unprepossessing pile of sooty black mess in ... University of Warwicks Department of Chemistry have found a way ... highly sensitive ready made electric circuit. , The research has ...
Cached Biology Technology:AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 2American Oriental Bioengineering Reports First Quarter 2008 Financial Results 3American Oriental Bioengineering Reports First Quarter 2008 Financial Results 4American Oriental Bioengineering Reports First Quarter 2008 Financial Results 5American Oriental Bioengineering Reports First Quarter 2008 Financial Results 6American Oriental Bioengineering Reports First Quarter 2008 Financial Results 7American Oriental Bioengineering Reports First Quarter 2008 Financial Results 8Nanotube production leaps from sooty mess in test tube to ready formed chemical microsensors 2
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... October 2011 - Genomatix is among the 41 partners ... Commission as a high impact project within its seventh ... sequencing data analysis and the development of an intuitive ... researchers within and outside the consortium. "To be ...
... that can strikingly reduce the number of risky diagnostic procedures ... to be introduced into clinical practice. The test can be ... who have been identified as being at high risk for ... study published online today in the journal Genetics in ...
... (UC Santa Barbara) Making waves as the ... a single layer of Carbon atoms has nonetheless ... be practical for innovative electronics applications. Researchers at UC ... quality graphene in a controlled manner that may pave ...
Cached Biology News:Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 2Study shows that new DNA test to identify Down syndrome in pregnancy is ready for clinical use 3New method of growing high-quality graphene promising for next-gen technology 2New method of growing high-quality graphene promising for next-gen technology 3
...
Buckets for tube holder inserts...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... a microprocessor controlled, high speed filter ... exceptionally smooth operation make the Lambda ... fluorescence microscopy, ratio imaging, spectrophotometry, visual ... and accurate aperture positioning. The Lambda ...
Biology Products: